- English
- Русский
ИНФЕКЦИЯ SARS-CоV-2 КАК ФАКТОР РИСКА РАЗВИТИЯ АУТОИММУНОЙ ПАТОЛОГИИ
DOI: https://doi.org/10.29296/24999490-2022-05-01
Актуальность: обзор посвящен анализу литературных данных о нарушениях работы иммунной системы при COVID-19. Так как некоторые клинические симптомы COVID-19 соответствуют признакам аутоиммунных заболеваний, один из фундаментальных вопросов патогенеза COVID-19, заключается в том, является ли инфицирование SARS-CoV-2 фактором риска развития аутоиммунных осложнений. Цель: оценка возможной роли гуморального ответа, в частности, антител с различной специфичностью при COVID-19, в развитии аутоиммунных реакций. Материал и методы: анализ и систематизация научных публикаций об аутоиммунных заболеваниях за последние 15 лет и о COVID-19 за 2020–2022 годы; поиск статей выполнен в базах данных PubMed и Scopus. Результаты: В данном обзоре проведено сравнение классических аутоиммунных заболеваний и COVID-19. Это сопоставление обусловлено и тем, что лечения тяжелых пациентов с COVID-19 практикуется использование препаратов, обычно назначаемых при аутоиммунных заболеваниях. Разнообразие аутоантител при COVID-19 может отражать временную иммунную активацию в условиях острой инфекции, а также раннюю потерю толерантности, и дальнейшее развитие хронической аутоиммунной патологии. Проведен обзор вирусных инфекций, запускающих аутоиммунные патологии, а также возможных механизмов индукции аутоиммунитета при COVID-19. Классифицированы и описаны основные группы антител, обнаруженные у пациентов с COVID-19.
Ключевые слова:
COVID-19, SARS-CoV-2, аутоиммунные заболевания, антитела, аутоиммунитет
Для цитирования:
Тимофеева А.М., Седых С.Е., Невинский Г.А. ИНФЕКЦИЯ SARS-CоV-2 КАК ФАКТОР РИСКА РАЗВИТИЯ АУТОИММУНОЙ ПАТОЛОГИИ. Молекулярная медицина, 2022; (5): 3-9https://doi.org/10.29296/24999490-2022-05-01
Список литературы:
- Albiol N., Awol R., Martino R. Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19. Ann Hematol. 2020; 99 (7): 1673–4. https://doi.org/10.1007/s00277-020-04097-0
- Malkova A.M., Kudryavtsev I.V., Starshinova A.A., Kudlay D.A., Zinchenko Yu.S., Glushkova A., Yablonskiy P., Shoenfeld Ye. Post COVID-19 syndrome in patients with asymptomatic/mild form. Pathogens. 2021; 10 (11), 1408: 1–11.
- Maeda Y., Nishikawa H., Sugiyama D. et al. Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals. Science (80-). 20 14; 346 (6216): 1536–40. https://doi.org/10.1126/science.aaa1292
- Hejrati A., Rafiei A., Soltanshahi M. et al. Innate immune response in systemic autoimmune diseases: a potential target of therapy. Inflammopharmacology. 2020; 28 (6): 1421–38. https://doi.org/10.1007/s10787-020-00762-y
- Shoenfeld Y. The mosaic of autoimmunity the role of environmental factors. Front Biosci. 2009; E1 (2): e46. https://doi.org/10.2741/e46
- Smatti M.K., Cyprian F.S., Nasrallah G.K., Al Thani A.A., Almishal R.O., Yassine H.M. Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms. Viruses. 2019; 11 (8): 762. https://doi.org/10.3390/v11080762
- Sene D., Piette J.-C., Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev. 2008; 7 (4): 272–7. https://doi.org/10.1016/j.autrev.2007.10.001
- Timofeeva A., Sedykh S., Nevinsky G. Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities. Vaccines. 2022; 10 (3): 384. https://doi.org/10.3390/vaccines10030384
- Abdel-Wahab N., Lopez-Olivo M.A., Pinto-Patarroyo G.P., Suarez-Almazor M.E. Systematic review of case reports of antiphospholipid syndrome following infection. Lupus. 2016; 25 (14): 1520–31. https://doi.org/10.1177/0961203316640912
- Козлов В.А., Тихонова Е.П., Савченко А.А., Кудрявцев И.В., Андронова Н.В., Анисимова Е.Н., Головкин А.С., Демина Д.В., Здзитовецкий Д.Э., Калинина Ю.С., Каспаров Э.В., Козлов И.Г., Корсунский И.А., Кудлай Д.А., Кузьмина Т.Ю., Миноранская Н.С., Продеус А.П., Старикова Э.А., Черданцев Д.В., Чесноков А.Б., П.А. Шестерня, А.Г. Борисов. Клиническая иммунология. Практическое пособие для инфекционистов. Красноярск: Поликор, 2021; 563. [Kozlov V.A., Tihonova E.P., Savchenko A.A., Kudryavcev I.V., Andronova N.V., Anisimova E.N., Golovkin A.S., Demina D.V., Zdzitoveckij D.E., Kalinina YU.S., Kasparov E.V., Kozlov I.G., Korsunskij I.A., Kudlaj D.A., Kuz’mina T.YU., Minoranskaya N.S., Prodeus A.P., Starikova E.A., CHerdancev D.V., CHesnokov A.B., P.A. SHesternya, A.G. Borisov. Clinical immunology. Prakticheskoe posobie dlya infekcionistov. Krasnoyarsk: Polikor, 2021; 563 (in Russian)].
- Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020; 46 (5): 846–8. https://doi.org/10.1007/s00134-020-05991-x
- Bastard P., Rosen L.B., Zhang Q. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science (80-). 2020; 370 (6515). https://doi.org/10.1126/science.abd4585
- Jenks S.A., Cashman K.S., Zumaquero E. et al. Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. Immunity. 2018; 49 (4): 725–39.e6. https://doi.org/10.1016/j.immuni.2018.08.015
- Zuo Y., Estes S.K., Ali R.A. et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020; 12 (570). https://doi.org/10.1126/scitranslmed.abd3876
- Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8 (4): 420–2. https://doi.org/10.1016/S2213-2600(20)30076-X
- Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
- Kanduc D., Shoenfeld Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine. Immunol Res. 2020; 68 (5): 310–3. https://doi.org/10.1007/s12026-020-09152-6
- Anand P., Puranik A., Aravamudan M., Venkatakrishnan A., Soundararajan V. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC. Elife. 2020; 9. https://doi.org/10.7554/eLife.58603
- Lucchese G., Flöel A. Molecular mimicry between SARS-CoV-2 and respiratory pacemaker neurons. Autoimmun Rev. 2020; 19 (7): 102556. https://doi.org/10.1016/j.autrev.2020.102556
- Marino Gammazza A., Légaré S., Lo Bosco G. et al. Human molecular chaperones share with SARS-CoV-2 antigenic epitopes potentially capable of eliciting autoimmunity against endothelial cells: possible role of molecular mimicry in COVID-19. Cell Stress Chaperones. 2020; 25 (5): 737–41. https://doi.org/10.1007/s12192-020-01148-3
- Lucchese G., Flöel A. SARS-CoV-2 and Guillain-Barré syndrome: molecular mimicry with human heat shock proteins as potential pathogenic mechanism. Cell Stress Chaperones. 2020; 25 (5): 731–5. https://doi.org/10.1007/s12192-020-01145-6
- Venkatakrishnan A.J., Kayal N., Anand P., Badley A.D., Church G.M., Soundararajan V. Benchmarking evolutionary tinkering underlying human–viral molecular mimicry shows multiple host pulmonary–arterial peptides mimicked by SARS-CoV-2. Cell Death Discov. 2020; 6 (1): 96. https://doi.org/10.1038/s41420-020-00321-y
- Rahimi K. Guillain-Barre syndrome during COVID-19 pandemic: an overview of the reports. Neurol Sci. 2020; 41 (11): 3149–56. https://doi.org/10.1007/s10072-020-04693-y
- Toscano G., Palmerini F., Ravaglia S. et al. Guillain–Barré Syndrome Associated with SARS-CoV-2. N. Engl. J. Med. 2020; 382 (26): 2574–6. https://doi.org/10.1056/NEJMc2009191
- Guan W., Ni Z., Hu Y. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020; 382 (18): 1708–20. https://doi.org/10.1056/NEJMoa2002032
- Mateu-Salat M., Urgell E., Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19. J. Endocrinol Invest. 2020; 43 (10): 1527–8. https://doi.org/10.1007/s40618-020-01366-7
- Lopez C., Kim J., Pandey A., Huang T., DeLoughery T.G. Simultaneous onset of COVID-19 and autoimmune haemolytic anaemia. Br. J. Haematol. 2020; 190 (1): 31–2. https://doi.org/10.1111/bjh.16786
- Akca U.K., Kesici S., Ozsurekci Y. et al. Kawasaki-like disease in children with COVID-19. Rheumatol Int. 2020; 40 (12): 2105–15. https://doi.org/10.1007/s00296-020-04701-6
- Marchand L., Pecquet M., Luyton C. Type 1 diabetes onset triggered by COVID-19. Acta Diabetol. 2020; 57 (10): 1265–6. https://doi.org/10.1007/s00592-020-01570-0
- Kazzaz N.M., McCune W.J., Knight J.S. Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol. 2016; 28 (3): 218–27. https://doi.org/10.1097/BOR.0000000000000269
- Cesarman-Maus G., Rios-Luna N.P., Deora A.B. et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood. 2006; 107 (11): 4375–82. https://doi.org/10.1182/blood-2005-07-2636
- Pascolini S., Vannini A., Deleonardi G. et al. COVID-19 and Immunological Dysregulation: Can Autoantibodies be Useful? Clin Transl Sci. 2021; 14 (2): 502–8. https://doi.org/10.1111/cts.12908
- Ehrenfeld M., Tincani A., Andreoli L. et al. Covid-19 and autoimmunity. Autoimmun Rev. 2020; 19 (8): 102597. https://doi.org/10.1016/j.autrev.2020.102597
- Canas F., Simonin L., Couturaud F., Renaudineau Y. Annexin A2 autoantibodies in thrombosis and autoimmune diseases. Thromb Res. 2015; 135 (2): 226–30. https://doi.org/10.1016/j.thromres.2014.11.034
- Jiang S.-L., Pan D.-Y., Gu C., Qin H.-F., Zhao S.-H. Annexin A2 silencing enhances apoptosis of human umbilical vein endothelial cells in vitro. Asian Pac J. Trop Med. 2015; 8 (11): 952–7. https://doi.org/10.1016/j.apjtm.2015.10.006
- Tešija Kuna A., Đerek L., Drvar V., Kozmar A., Gugo K. Assessment of antinuclear antibodies (ANA): National recommendations on behalf of the Croatian society of medical biochemistry and laboratory medicine. Biochem medica. 2021; 31 (2): 210–29. https://doi.org/10.11613/BM.2021.020502
- Agmon-Levin N., Damoiseaux J., Kallenberg C. et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014; 73 (1): 17–23. https://doi.org/10.1136/annrheumdis-2013-203863
- Zhou Y., Han T., Chen J. et al. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19. Clin Transl Sci. 2020; 13 (6): 1077–86. https://doi.org/10.1111/cts.12805
- Vlachoyiannopoulos P.G., Magira E., Alexopoulos H. et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020; 79 (12): 1661–3. https://doi.org/10.1136/annrheumdis-2020-218009
- Nevinsky G.A. Autoimmune Processes in Multiple Sclerosis: Production of Harmful Catalytic Antibodies Associated with Significant Changes in the Hematopoietic Stem Cell Differentiation and Proliferation. In: Trending Topics in Multiple Sclerosis. InTech. 2016. https://doi.org/10.5772/63824
- Nevinsky G.A. The extreme diversity of autoantibodies and abzymes against different antigens in patients with various autoimmune diseases. In: Advances in Medicine and Biology. 2021; 1–130.
- Ermakov E.A., Smirnova L.P., Parkhomenko T.A. et al. DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophrenia. Open Biol. 2015; 5 (9): 150064. https://doi.org/10.1098/rsob.150064
- Nevinsky G.A. Catalytic Antibodies in Norm and Systemic Lupus Erythematosus. In: Lupus. InTech. 2017. https://doi.org/10.5772/67790
- Ermakov E.A., Nevinsky G.A., Buneva V.N. Immunoglobulins with Non-Canonical Functions in Inflammatory and Autoimmune Disease States. Int J. Mol. Sci. 2020; 21 (15): 5392. https://doi.org/10.3390/ijms21155392
- Timofeeva A., Sedykh S., Maksimenko L. et al. The Blood of the HIV-Infected Patients Contains κ-IgG, λ-IgG, and Bispecific κλ-IgG, Which Possess DNase and Amylolytic Activity. Life. 2022; 12 (2): 304. https://doi.org/10.3390/life12020304
- Wang E.Y., Mao T., Klein J. et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021; 595 (7866): 283–8. https://doi.org/10.1038/s41586-021-03631-y
- Guilmot A., Maldonado Slootjes S., Sellimi A. et al. Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. J. Neurol. 2021; 268 (3): 751–7. https://doi.org/10.1007/s00415-020-10108-x
- Franke C., Ferse C., Kreye J. et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav Immun. 2021; 93: 415–9. https://doi.org/10.1016/j.bbi.2020.12.022
- Delamarre L., Gollion C., Grouteau G. et al. COVID-19–associated acute necrotising encephalopathy successfully treated with steroids and polyvalent immunoglobulin with unusual IgG targeting the cerebral fibre network. J. Neurol Neurosurg Psychiatry. 2020; 91 (9): 1004–6. https://doi.org/10.1136/jnnp-2020-323678
- Pinto A.A., Carroll L.S., Nar V., Varatharaj A., Galea I. CNS inflammatory vasculopathy with antimyelin oligodendrocyte glycoprotein antibodies in COVID-19. Neurol – Neuroimmunol Neuroinflammation. 2020; 7 (5): e813. https://doi.org/10.1212/NXI.0000000000000813
- Jensen C.E., Wilson S., Thombare A., Weiss S., Ma A. Cold agglutinin syndrome as a complication of Covid-19 in two cases. Clin Infect Pract. 2020; 7–8: 100041. https://doi.org/10.1016/j.clinpr.2020.100041
- Berzuini A., Bianco C., Paccapelo C. et al. Red cell–bound antibodies and transfusion requirements in hospitalized patients with COVID-19. Blood. 2020; 136 (6): 766–8. https://doi.org/10.1182/blood.2020006695
- Casciola-Rosen L., Thiemann D.R., Andrade F. et al. IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. JCI Insight. 2022; 7 (9). https://doi.org/10.1172/jci.insight.158362